Weybosset Research & Management LLC Grows Stock Position in Biohaven Ltd. (NYSE:BHVN)

Weybosset Research & Management LLC grew its position in shares of Biohaven Ltd. (NYSE:BHVN) by 23.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,645 shares of the company’s stock after purchasing an additional 2,635 shares during the period. Biohaven makes up about 0.2% of Weybosset Research & Management LLC’s investment portfolio, making the stock its 29th largest position. Weybosset Research & Management LLC’s holdings in Biohaven were worth $510,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. nVerses Capital LLC purchased a new position in Biohaven in the 3rd quarter valued at about $50,000. Redwood Wealth Management Group LLC purchased a new position in Biohaven in the second quarter valued at about $61,000. Values First Advisors Inc. acquired a new stake in Biohaven during the 3rd quarter valued at approximately $78,000. US Bancorp DE increased its holdings in Biohaven by 57.1% during the 3rd quarter. US Bancorp DE now owns 2,173 shares of the company’s stock worth $109,000 after purchasing an additional 790 shares during the last quarter. Finally, KBC Group NV raised its position in shares of Biohaven by 24.5% in the 3rd quarter. KBC Group NV now owns 2,250 shares of the company’s stock valued at $112,000 after purchasing an additional 443 shares in the last quarter. 88.78% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director John W. Childs bought 29,000 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The shares were acquired at an average cost of $35.94 per share, for a total transaction of $1,042,260.00. Following the acquisition, the director now directly owns 2,368,741 shares of the company’s stock, valued at $85,132,551.54. The trade was a 1.24 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 16.00% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts recently issued reports on BHVN shares. Bank of America lifted their price target on shares of Biohaven from $52.00 to $62.00 and gave the stock a “buy” rating in a research note on Tuesday, September 24th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Biohaven in a research report on Tuesday, December 17th. Sanford C. Bernstein boosted their price objective on Biohaven from $55.00 to $66.00 and gave the company an “outperform” rating in a report on Tuesday, September 24th. HC Wainwright reaffirmed a “buy” rating and set a $59.00 target price on shares of Biohaven in a report on Tuesday, December 17th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $61.00 price target (up from $58.00) on shares of Biohaven in a report on Wednesday, December 4th. Thirteen analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $63.00.

Biohaven Stock Down 2.5 %

Biohaven stock traded down $0.97 during mid-day trading on Friday, hitting $38.20. 718,139 shares of the company’s stock traded hands, compared to its average volume of 908,545. Biohaven Ltd. has a one year low of $26.80 and a one year high of $62.21. The company has a market cap of $3.86 billion, a PE ratio of -4.09 and a beta of 1.29. The firm has a 50 day moving average price of $43.19 and a 200 day moving average price of $42.19.

Biohaven (NYSE:BHVN) last released its earnings results on Tuesday, November 12th. The company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.67) by ($0.03). On average, analysts expect that Biohaven Ltd. will post -8.85 earnings per share for the current fiscal year.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.